Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;4(12):1920-4.
doi: 10.2215/CJN.02730409. Epub 2009 Oct 9.

Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome

Joshua M Thurman  1 , Russell Marians, Woodruff Emlen, Susan Wood, Christopher Smith, Hillary Akana, V Michael Holers, Martin Lesser, Myriam Kline, Cathy Hoffman, Erica Christen, Howard Trachtman
Affiliations

Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome

Joshua M Thurman et al. Clin J Am Soc Nephrol. 2009 Dec.

Abstract

Background and objectives: Diarrhea-associated hemolytic uremic syndrome (D+HUS) is a common cause of acute kidney injury in children. Mutations in alternative pathway (AP) complement regulatory proteins have been identified in severe cases of thrombotic microangiopathy, but the role of the AP in D+HUS has not been studied. Therefore, we determined whether plasma levels of markers of activation of the AP are increased in D+HUS and are biomarkers of the severity of renal injury that predict the need for dialysis.

Design, setting, participants, & measurements: Patients were randomly selected from among participants in the HUS-SYNSORB Pk trial. Plasma samples were collected on days 1, 4, 7, and 10 after enrollment and day 28 after discharge from the hospital. Levels of two complement pathway products, Bb and SC5b-9, were determined by ELISA.

Results: Seventeen children (6 boys and 11 girls; age, 5.4 +/- 3.5 yr) were studied. Eight (47%) required dialysis support, and two had serious extrarenal events. On the day of enrollment, plasma levels of Bb and SC5b-9 were significantly increased in all patients compared with healthy controls (P < 0.01). The elevated concentrations normalized by day 28 after discharge. Circulating levels of complement pathway fragments did not correlate with severity of renal injury or occurrence of complications.

Conclusions: Patients with acute-onset D+HUS manifest activation of the AP of complement that is temporally related to the onset of disease and that resolves within 1 mo. Therapies to inhibit the AP of complement may be useful in attenuating the severity of renal injury and extrarenal complications.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The bar graphs show the mean plasma concentration of Bb (A) and SC5b-9 (B) in patients with D+HUS on day 1 of their illness and at day 28 after hospitalization. The mean value for each AP of complement fragment in normal controls (n = 4) is included in each panel.
Figure 2.
Figure 2.
The graphs show the plasma concentration of Bb (A) and SC5b-9 (B) over the course of the D+HUS episode in a patient who required dialysis [(+)HD] and in a patient who was treated with conservative medical management for the acute kidney injury [(−)HD].
Figure 3.
Figure 3.
The bar graph shows the mean peak concentration of Bb and SC5b-9 in patients with required renal replacement therapy and those who did not need this supportive treatment.
See this image and copyright information in PMC

References

    1. Tarr PI, Gordon CA, Chandler WL: Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365: 1073–1086, 2005 - PubMed
    1. Hughes AK, Ergonul Z, Stricklett PK, Kohan DE: Molecular basis for high renal cell sensitivity to the cytotoxic effects of Shigatoxin-1: Upregulation of globotriaosylceramide expression. J Am Soc Nephrol 13: 2239–2245, 2002 - PubMed
    1. Proulx F, Toledano B, Phan V, Clermont MJ, Mariscalco MM, Seidman EG: Circulating granulocyte colony-stimulating factor, C-X-C, and C-C chemokines with Escherichia coli O157:H7 associated with hemolytic uremic syndrome. Pediatr Res 52: 928–934, 2002 - PubMed
    1. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB: A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 70: 423–431, 2006 - PubMed
    1. Robson WL, Leung AK, Fick GHG, McKenna AI: Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 62: 296–298, 1992 - PubMed

Publication types

MeSH terms